Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Ovarian ablation by radiation therapy: Is it still an option for the ablation of ovarian function in endocrine responsive premenopausal breast cancer patients?
The Breast, 10/08/09

Bese NS et al. – RA should be considered as an option for endocrine responsive premenopausal breast cancer patients and can be easily delivered when postoperative or palliative irradiation is given.

Methods

Efficacy and toxicity of radiation therapy (RT) for ovarian function suppression in 118 premenopausal breast cancer patients retrospectively evaluated
Median age 39 years (range 21–52 years)
RT given with either Co-60 or 15MV photons of linear accelerator
Median total dose 15Gy in 4 consecutive fractions
Endpoint for treatment efficacy menstrual status

Results

Amenorrhea noted in 113 of 118 patients (96%) in 6 months following RA
5 patients (4%) who had still normal menstrual functioning after 6 months of RA underwent estradiol and FSH measurements and found to have premenopausal levels
No acute Grade 3 or 4 (according to the Radiation Therapy Oncology Group radiation morbidity scoring criteria) toxicities noted
Median follow-up of 24.5 months (range: 6–167), no late severe complications that could be attributable to RT reported

<< Previous
MicroRNA expression, survival, and response to Interferon in...

Next >>
Multinational, double-blind, phase III study of prednisone and...